The molecular diagnostic products and services supplied by MolecularMD are specifically intended to help navigate the significant challenges facing developers of targeted cancer treatments. Our assays are designed to meet clinical performance requirements and, at the same time, address the healthcare considerations of patients, doctors, and payors.
Together with our pharmaceutical clients, we aim to better understand the link between molecular response and improved survival.
MolecularMD and Mayo Clinic Enter into Sub-License Agreement for the Detection of Drug Resistant Mutations in Leukemia Patients.
Read Full Article >
